{"organizations": [], "uuid": "3a5d0c6eb9c5666ad5d149c98a1000b44d414dd6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180122.html", "section_title": "Archive News &amp; Video for Monday, 22 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-shenzhen-neptunus-bioengineering-u/brief-shenzhen-neptunus-bioengineering-unit-passes-fda-approval-for-new-drug-clinical-trial-idUSL4N1PH31Z", "country": "US", "domain_rank": 408, "title": "BRIEF-Shenzhen Neptunus Bioengineering unit passes FDA approval for new drug clinical trial", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.995, "site_type": "news", "published": "2018-01-22T16:17:00.000+02:00", "replies_count": 0, "uuid": "3a5d0c6eb9c5666ad5d149c98a1000b44d414dd6"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-shenzhen-neptunus-bioengineering-u/brief-shenzhen-neptunus-bioengineering-unit-passes-fda-approval-for-new-drug-clinical-trial-idUSL4N1PH31Z", "ord_in_thread": 0, "title": "BRIEF-Shenzhen Neptunus Bioengineering unit passes FDA approval for new drug clinical trial", "locations": [], "entities": {"persons": [], "locations": [{"name": "united states", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "shenzhen neptunus bioengineering co ltd", "sentiment": "negative"}, {"name": "brief-shenzhen neptunus bioengineering", "sentiment": "negative"}, {"name": "beijing headline news", "sentiment": "none"}, {"name": "u.s food and drug administration", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 22(Reuters) - Shenzhen Neptunus Bioengineering Co Ltd :\n* Says its wholly owned pharma tech unit received FDA approval for anti-tumor new drug clinical trail from U.S Food and Drug Administration\n* The unit will be able to conduct clinical trial of anti-tumor new drug in the United States after receiving the FDA approval\nSource text in Chinese: goo.gl/Ucdtfz\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "https://goo.gl/Ucdtfz"], "published": "2018-01-22T16:17:00.000+02:00", "crawled": "2018-01-23T17:51:30.000+02:00", "highlightTitle": ""}